Tango Therapeutics, Inc. Financing Cash Flow
Tango Therapeutics, Inc. (TNGX) reported Financing Cash Flow of $752.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $672.57M, a 115660.59% increase year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $79.85M, a 3992200.00% increase year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $219.38M, a 22539.42% increase year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.54M, a 5.79% increase year-over-year.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $222.50M, a 366.81% increase from fiscal 2024.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $47.66M, a 42.16% decline from fiscal 2023.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $82.41M, a 5002.54% increase from fiscal 2022.
- Tango Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $1.61M, a 99.55% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 1 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 7 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $672.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $752.41M 10-Q · filed 2026-08-11 | $971.79M derived: sum of 3 quarters · filed 2026-08-11 | $974.33M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $79.85M 10-Q · filed 2026-05-13 | $299.22M derived: sum of 2 quarters · filed 2026-05-13 | $301.76M derived: sum of 3 quarters · filed 2026-05-13 | $302.34M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $219.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $221.92M derived: sum of 2 quarters · filed 2026-03-05 | $222.50M derived: sum of 3 quarters · filed 2026-08-11 | $222.50M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.12M derived: sum of 2 quarters · filed 2026-08-11 | $3.12M 10-Q · filed 2025-11-04 | $4.09M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $581.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $583.00K 10-Q · filed 2026-08-11 | $1.55M derived: sum of 3 quarters · filed 2026-08-11 | $3.95M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $2.00K 10-Q · filed 2026-05-13 | $971.00K derived: sum of 2 quarters · filed 2026-05-13 | $3.37M derived: sum of 3 quarters · filed 2026-05-13 | $4.68M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $969.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.37M derived: sum of 2 quarters · filed 2026-03-05 | $4.68M derived: sum of 3 quarters · filed 2026-03-05 | $47.66M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.71M derived: sum of 2 quarters · filed 2025-11-04 | $46.70M 10-Q · filed 2025-11-04 | $48.16M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $44.29M 10-Q · filed 2025-08-05 | $45.76M derived: sum of 3 quarters · filed 2026-03-05 | $126.04M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-03-31 | $42.98M 10-Q · filed 2025-05-12 | $44.45M derived: sum of 2 quarters · filed 2026-03-05 | $124.73M derived: sum of 3 quarters · filed 2026-03-05 | $125.31M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2023-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $81.75M derived: sum of 2 quarters · filed 2026-03-05 | $82.33M derived: sum of 3 quarters · filed 2026-03-05 | $82.41M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $80.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $80.87M derived: sum of 2 quarters · filed 2024-11-06 | $80.94M 10-Q · filed 2024-11-06 | $81.47M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $586.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $659.00K 10-Q · filed 2024-08-07 | $1.19M derived: sum of 3 quarters · filed 2025-02-27 | $1.30M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $73.00K 10-Q · filed 2024-05-08 | $600.00K derived: sum of 2 quarters · filed 2025-02-27 | $713.00K derived: sum of 3 quarters · filed 2025-02-27 | $1.43M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $640.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.36M derived: sum of 3 quarters · filed 2025-02-27 | $1.61M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $831.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.09M 10-Q · filed 2023-11-08 | $968.00K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $718.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $975.00K 10-Q · filed 2023-08-07 | $855.00K derived: sum of 3 quarters · filed 2023-08-07 | $328.63M derived: sum of 4 quarters · filed 2023-08-07 | |||
| 2022-03-31 | $257.00K 10-Q · filed 2023-05-09 | $137.00K derived: sum of 2 quarters · filed 2023-05-09 | $327.92M derived: sum of 3 quarters · filed 2023-05-09 | $327.17M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $327.66M derived: sum of 2 quarters · filed 2023-03-27 | $326.91M derived: sum of 3 quarters · filed 2023-03-27 | $357.32M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $327.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $327.03M derived: sum of 2 quarters · filed 2022-11-10 | $357.44M 10-Q · filed 2022-11-10 | $357.38M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $29.66M 10-Q · filed 2022-08-10 | $29.60M derived: sum of 3 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $30.41M 10-Q · filed 2022-05-11 | $30.35M derived: sum of 2 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $168.39M 10-K · filed 2021-03-31 | $80.88M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | $168.39M 10-Q · filed 2020-11-13 | $80.94M 10-Q · filed 2021-11-09 | |||||
| 2020-06-30 | $25.02K 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |